NGNE 8-K 2026-11-09

Neurogene Inc. (NGNE) 8-K dated 2026-11-09 — accession 0001404644-26-000064.

Neurogene Inc. (NGNE) is a biotechnology company listed on US.

NGNE: Neurogene Reports Third Quarter 2026 Financial Results and Highlights R…

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported NGNE revenue for 2025-12-31 was $0. Net income was -$90.4M. Revenue was down 100.0% from 2024-12-31 to 2025-12-31. NGNE currently screens at market cap $286.5M.

Not investment advice. The NGNE SEC hub lists recent forms. The stock page is the research view.